Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary AngioedemaBusiness Wire • 12/08/20
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding DisordersBusiness Wire • 12/07/20
Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]Business Wire • 12/02/20
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia PacificBusiness Wire • 11/30/20
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company LimitedBusiness Wire • 11/30/20
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19PRNewsWire • 11/30/20
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with TakedaBusiness Wire • 11/26/20
Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual MeetingBusiness Wire • 11/09/20
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual MeetingBusiness Wire • 11/05/20
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/30/20
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPSBusiness Wire • 10/29/20
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of JapanBusiness Wire • 10/29/20
Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to JapanBusiness Wire • 10/29/20
Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020Business Wire • 10/27/20
Takeda-Led Group Begins Manufacturing COVID-19 Plasma Treatment, Says Confident Of EfficacyBenzinga • 10/13/20
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver DiseaseBusiness Wire • 10/08/20
Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer PortfolioBusiness Wire • 09/18/20